Description de l'entreprise
Illumina is improving human health by unlocking the power of the genome. The company's focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Illumina's products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments.
Conseil d'administration & Conseil de surveillance
| PDG |
| Charles Dadswell |
| Conseil d'administration |
| Ankur Dhingra, Steve Barnard, Nicole Berry, Aimee Hoyt, Kevin Pegels, Li Qing, Kathryne Reeves, Carissa Rollins, Salli Schwartz, Susan Tousi, Bas Verhoef, Gretchen Weightman |
| Conseil de surveillance |
| Stephen P. MacMillan, Frances Arnold, PhD, Caroline Dorsa, Robert S. Epstein, Scott Gottlieb, Gary S. Guthart, Philip Schiller, Sue Siegel, Andrew Teno, Scott B. Ullem |
Données de l'entreprise
| Nom: |
Illumina Inc. |
| Adresse: |
5200 Illumina Way,San Diego, California 92122, USA |
| Téléphone: |
+1-858-202-4500 |
| Fax: |
+1-858-202-4766 |
| Courriel: |
info@illumina.com
|
| Internet: |
www.illumina.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Medical Products |
| Sous-secteur: |
Advanced Medical Devices |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
48.29% |
| IPO date: |
28/07/2000 |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
+1-858-291-6421 |
| IR-Fax: |
- |
| E-mail IR: |
ir@illumina.com
|
